Meta-Analysis Plan for an analysis to compare the addition of Umeclidinium Inhalation Powder 62.5mcg to ICS/LABA with Placebo plus ICS/LABA in subjects with Chronic Obstructive Pulmonary Disease (COP...

Update Il y a 5 ans
Reference: GSK202067

Meta-Analysis Plan for an analysis to compare the addition of Umeclidinium Inhalation Powder 62.5mcg to ICS/LABA with Placebo plus ICS/LABA in subjects with Chronic Obstructive Pulmonary Disease (COPD)

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract


Links